She could have built a research career in the US, instead, she stayed back to build a drug for millions living with vitiligo

<a href="https://timesofindia.indiatimes.com/education/news/she-could-have-built-a-research-career-in-the-us-instead-she-stayed-back-to-build-a-drug-for-millions-living-with-vitiligo/articleshow/132252848.cms"><img border="0" hspace="10" align="left" style="margin-top:3px;margin-right:5px;" src="https://timesofindia.indiatimes.com/photo/132252848.cms" /></a>Dr Parul Ganju chose to forgo a US research opportunity to focus on developing a treatment for vitiligo after witnessing its profound impact on patients. In 2016, she co-founded Ahammune Biosciences, where the lead drug candidate, AB1001, targets the disease's underlying immune pathway rather than broadly suppressing immunity. Now in Phase 2 clinical trials, the investigational therapy reflects her commitment to translating scientific research into potential treatments that could improve millions of lives.< a href="https://timesofindia.indiatimes.com/education/news/she-could-have-built-a-research-career-in-the-us-instead-she-stayed-back-to-build-a-drug-for-millions-living-with-vitiligo/articleshow/132252848.cms">READ MORE